NORGESIC TABLET

Страна: Сингапур

Език: английски

Източник: HSA (Health Sciences Authority)

Активна съставка:

ORPHENADRINE CITRATE; PARACETAMOL

Предлага се от:

INOVA PHARMACEUTICALS (SINGAPORE) PTE. LIMITED

АТС код:

M03BC51

дозиране:

35 mg

Лекарствена форма:

TABLET

Композиция:

ORPHENADRINE CITRATE 35 mg; PARACETAMOL 450 mg

Начин на приложение:

ORAL

Вид предписание :

Prescription Only

Произведено от:

Adcock Ingram Limited

Статус Оторизация:

ACTIVE

Дата Оторизация:

1991-03-20

Листовка

PRODUCT INFORMATION
LT006901
NORGESIC
COMPOSITION
Each tablet contains orphenadrine citrate 35mg, paracetamol
450mg.
ACTIONS
Orphenadrine is a skeletal muscle relaxant.
Paracetamol is an analgesic and antipyretic.
INDICATIONS
Tension headache, occipital headaches associated with spasm
of skeletal muscles in the region of the head and neck. Acute
and traumatic conditions of the limbs and trunk: sprains, strains,
whiplash injuries, acute torticollis, prolapsed intervertebral disc.
CONTRAINDICATIONS
Orphenadrine shows some anticholinergic activity and should
not be used in patients with glaucoma, prostatic hypertrophy or
obstruction at the bladder neck, or myasthenia gravis.
PRECAUTIONS
Orphenadrine may impair the ability of the patient to engage in
potentially hazardous activities such as operating machinery or
driving a motor vehicle; ambulatory patients should therefore be
cautioned accordingly.
Orphenadrine citrate should be used with caution in patients
with tachycardia, cardiac decompensation, coronary
insufficiency, cardiac arrhythmias.
Safety of continuous long-term therapy with orphenadrine has
not been established. Therefore if orphenadrine is prescribed
for prolonged use, periodic monitoring of blood, urine and liver
function is recommended.
USE IN PREGNANCY
Safe use in pregnancy has not been established, therefore the
drug should not be used in pregnant women or those likely to
become pregnant unless the expected benefits outweigh the
potential risks.
DRUG INTERACTIONS
The effects of antimuscarinic agents such as orphenadrine
maybe enhanced by other drugs with antimuscarinic properties
such as amantadine, some antihistamines, butyrophenones and
phenothiazines, and tricyclic antidepressants. The reduction
PLEASE NOTE: THIS IS A LOW RESOLUTION PDF & IS NOT TO BE USED AS
FINAL ARTWORK
Comments
VERSION 
1
5
10
20
30
40
50
60
70
80
95
100
Signatures
12.05.14 - New artwork build - Schee               
16.06.14 - Add Address - Schee 
DATE ....................................
12.05.14
LEAD MARK

Данни за продукта

PLEASE NOTE: THIS IS A LOW RESOLUTION PDF & IS NOT TO BE USED FOR
PRINTING
PRODUCT
BRAND: Norgesic
PRODUCT VARIANT:
Skeletal Muscle Relaxant With Analgesic
PACK SIZE: 600 Tablets
COUNTRY: SINGAPORE
DATE: 05/09/2018
COMPONENT: Leaflet
DIMENSIONS: 153 w x 187 h
DIELINE REF:
Norgesic Tablets - SL - English - PIL_Cutterguide
PRINTER: N/A
ARTWORK SOFTWARE: Illustrator CC 2017
BARCODE %: Edit
SIGNED:
ARTWORKER:
DATE: 00/00/2018
EMO: Adcock
SKU NO: 103745
PRINTER DETAILS
FONTS USED:
Helvetica Bold
Helvetica Regular
BODY COPY SIZE: 6pts
MIN. FONT SIZE: 1.5mm
FONTS
CODES
APPROVALS
UIC: LT0122
24/08/18 : New Artwork Build - Yuki
03/09/18 : Amends - Elaine
05/09/18 : Amends - Yuki
AMENDS
ARTWORKER INFO
COLOURS
VERSION: 2
JOB NO: 83758
BLACK
FILENAME:
83758_LT0122_NG_SMRWA
_600_Leaflet_SG_V2.ai
LT0122
PRODUCT INFORMATION
NORGESIC
®
LT0122
XXXXXXX
Revision date: September 2018
COMPOSITION
Each tablet contains orphenadrine citrate 35mg, paracetamol 450mg.
ACTIONS
Orphenadrine is a skeletal muscle relaxant. Paracetamol is an
analgesic and antipyretic.
INDICATIONS
Tension headache, occipital headaches associated with spasm of
skeletal muscles in the region of the
head and neck. Acute and traumatic conditions of the limbs and trunk:
sprains, strains, whiplash injuries,
acute torticollis, prolapsed intervertebral disc.
CONTRAINDICATIONS
Orphenadrine shows some anticholinergic activity and should not be
used in patients with glaucoma,
prostatic hypertrophy or obstruction at the bladder neck, or
myasthenia gravis.
PRECAUTIONS
Orphenadrine may impair the ability of the patient to engage in
potentially hazardous activities such as
operating machinery or driving a motor vehicle; ambulatory patients
should therefore be
cautioned accordingly.
Orphenadrine citrate should be used with caution in patients with
tachycardia, cardiac decompensation,
coronary insufficiency, cardiac arrhythmias.
Safety of continuous long-term therapy with orphenadrine has not been
established. Therefore if
orphenadrine is prescribed for prolonged use, periodic